blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3236966

EP3236966 - COMBINATION OF RAF INHIBITORS AND TAXANES [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  18.06.2021
Database last updated on 29.10.2024
FormerThe patent has been granted
Status updated on  10.07.2020
FormerGrant of patent is intended
Status updated on  02.03.2020
FormerRequest for examination was made
Status updated on  29.09.2017
FormerThe international publication has been made
Status updated on  19.07.2017
Most recent event   Tooltip15.07.2022Lapse of the patent in a contracting state
New state(s): MK, PT		published on 17.08.2022  [2022/33]
Applicant(s)For all designated states
DOT Therapeutics-1, Inc.
2765 Sand Hill Road
Menlo Park, CA 94025 / US
[2020/18]
Former [2017/44]For all designated states
Millennium Pharmaceuticals, Inc.
40 Landsdowne Street
Cambridge, MA 02139 / US
Inventor(s)01 / BOZON, Viviana
99 Pickwick Road
West Newton, MA 02465 / US
02 / GALVIN, Katherine M.
52 Greenlawn Avenue
Newton, MA 02459 / US
03 / BRAKE, Rachael L.
21 Manchester Place
Natick, MA 01760 / US
04 / XU, Qunli
43 Nothgate Road
Wellesley, MA 02481 / US
05 / KANNAN, Karuppiah
47 Auburn Street
Newton, MA 02465 / US
 [2020/33]
Former [2017/44]01 / BOZON, Viviana
99 Pickwick Road
West Newton, MA 02465 / US
02 / GALVIN, Katherine, M.
52 Greenlawn Avenue
Newton, MA 02459 / US
03 / BRAKE, Rachael, L.
21 Manchester Place
Natick, MA 01760 / US
04 / XU, Qunli
43 Nothgate Road
Wellesley, MA 02481 / US
05 / KANNAN, Karuppiah
47 Auburn Street
Newton, MA 02465 / US
Representative(s)Harris, Jennifer Lucy
Kilburn & Strode LLP
Lacon London
84 Theobalds Road
London WC1X 8NL / GB
[2017/44]
Application number, filing date15874331.022.12.2015
[2017/44]
WO2015US67462
Priority number, dateUS201462096020P23.12.2014         Original published format: US 201462096020 P
US201562242629P16.10.2015         Original published format: US 201562242629 P
[2017/44]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2016106359
Date:30.06.2016
Language:EN
[2016/26]
Type: A1 Application with search report 
No.:EP3236966
Date:01.11.2017
Language:EN
The application published by WIPO in one of the EPO official languages on 30.06.2016 takes the place of the publication of the European patent application.
[2017/44]
Type: B1 Patent specification 
No.:EP3236966
Date:12.08.2020
Language:EN
[2020/33]
Search report(s)International search report - published on:US30.06.2016
(Supplementary) European search report - dispatched on:EP31.08.2018
ClassificationIPC:A61K31/506, A61K31/428, A61K31/337, A61K45/06, A61P35/00, A61K31/505
[2018/39]
CPC:
A61K31/506 (EP,US); A61K31/337 (EP,US); A61K31/428 (EP,US);
A61K45/06 (EP,US); A61P35/00 (EP,US)
C-Set:
A61K31/337, A61K2300/00 (EP,US);
A61K31/428, A61K2300/00 (US,EP);
A61K31/506, A61K2300/00 (US,EP)
Former IPC [2017/44]A61K31/505
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2017/44]
Extension statesBANot yet paid
MENot yet paid
Validation statesMANot yet paid
MDNot yet paid
TitleGerman:KOMBINATION AUS RAF-HEMMERN UND TAXANEN[2017/44]
English:COMBINATION OF RAF INHIBITORS AND TAXANES[2017/44]
French:COMBINAISON D'INHIBITEURS DE RAF ET DE TAXANES[2017/44]
Entry into regional phase19.07.2017National basic fee paid 
19.07.2017Search fee paid 
19.07.2017Designation fee(s) paid 
19.07.2017Examination fee paid 
Examination procedure19.07.2017Examination requested  [2017/44]
19.07.2017Date on which the examining division has become responsible
26.03.2019Amendment by applicant (claims and/or description)
03.03.2020Communication of intention to grant the patent
06.07.2020Fee for grant paid
06.07.2020Fee for publishing/printing paid
06.07.2020Receipt of the translation of the claim(s)
Opposition(s)14.05.2021No opposition filed within time limit [2021/29]
Fees paidRenewal fee
27.12.2017Renewal fee patent year 03
31.12.2018Renewal fee patent year 04
27.12.2019Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU22.12.2015
AL12.08.2020
AT12.08.2020
CY12.08.2020
CZ12.08.2020
DK12.08.2020
EE12.08.2020
FI12.08.2020
HR12.08.2020
LT12.08.2020
LV12.08.2020
MK12.08.2020
MT12.08.2020
NL12.08.2020
PL12.08.2020
PT12.08.2020
RO12.08.2020
RS12.08.2020
SE12.08.2020
SI12.08.2020
SK12.08.2020
SM12.08.2020
TR12.08.2020
BG12.11.2020
NO12.11.2020
GR13.11.2020
IS12.12.2020
[2022/32]
Former [2022/27]HU22.12.2015
AL12.08.2020
AT12.08.2020
CY12.08.2020
CZ12.08.2020
DK12.08.2020
EE12.08.2020
FI12.08.2020
HR12.08.2020
LT12.08.2020
LV12.08.2020
MT12.08.2020
NL12.08.2020
PL12.08.2020
RO12.08.2020
RS12.08.2020
SE12.08.2020
SI12.08.2020
SK12.08.2020
SM12.08.2020
TR12.08.2020
BG12.11.2020
NO12.11.2020
GR13.11.2020
IS12.12.2020
Former [2021/36]AL12.08.2020
AT12.08.2020
CZ12.08.2020
DK12.08.2020
EE12.08.2020
FI12.08.2020
HR12.08.2020
LT12.08.2020
LV12.08.2020
NL12.08.2020
PL12.08.2020
RO12.08.2020
RS12.08.2020
SE12.08.2020
SI12.08.2020
SK12.08.2020
SM12.08.2020
BG12.11.2020
NO12.11.2020
GR13.11.2020
IS12.12.2020
Former [2021/28]AL12.08.2020
AT12.08.2020
CZ12.08.2020
DK12.08.2020
EE12.08.2020
FI12.08.2020
HR12.08.2020
LT12.08.2020
LV12.08.2020
NL12.08.2020
PL12.08.2020
RO12.08.2020
RS12.08.2020
SE12.08.2020
SK12.08.2020
SM12.08.2020
BG12.11.2020
NO12.11.2020
GR13.11.2020
IS12.12.2020
Former [2021/25]AL12.08.2020
AT12.08.2020
CZ12.08.2020
DK12.08.2020
EE12.08.2020
FI12.08.2020
HR12.08.2020
LT12.08.2020
LV12.08.2020
NL12.08.2020
PL12.08.2020
RO12.08.2020
RS12.08.2020
SE12.08.2020
SM12.08.2020
BG12.11.2020
NO12.11.2020
GR13.11.2020
IS12.12.2020
Former [2021/23]AT12.08.2020
CZ12.08.2020
DK12.08.2020
EE12.08.2020
FI12.08.2020
HR12.08.2020
LT12.08.2020
LV12.08.2020
NL12.08.2020
PL12.08.2020
RO12.08.2020
RS12.08.2020
SE12.08.2020
SM12.08.2020
BG12.11.2020
NO12.11.2020
GR13.11.2020
IS12.12.2020
Former [2021/22]CZ12.08.2020
DK12.08.2020
EE12.08.2020
FI12.08.2020
HR12.08.2020
LT12.08.2020
LV12.08.2020
NL12.08.2020
PL12.08.2020
RO12.08.2020
RS12.08.2020
SE12.08.2020
BG12.11.2020
NO12.11.2020
GR13.11.2020
IS12.12.2020
Former [2021/21]DK12.08.2020
FI12.08.2020
HR12.08.2020
LT12.08.2020
LV12.08.2020
NL12.08.2020
PL12.08.2020
RS12.08.2020
SE12.08.2020
BG12.11.2020
NO12.11.2020
GR13.11.2020
IS12.12.2020
Former [2021/12]FI12.08.2020
HR12.08.2020
LT12.08.2020
LV12.08.2020
NL12.08.2020
PL12.08.2020
RS12.08.2020
SE12.08.2020
BG12.11.2020
NO12.11.2020
GR13.11.2020
IS12.12.2020
Former [2021/10]FI12.08.2020
HR12.08.2020
LT12.08.2020
LV12.08.2020
PL12.08.2020
RS12.08.2020
SE12.08.2020
BG12.11.2020
NO12.11.2020
GR13.11.2020
IS12.12.2020
Former [2021/09]FI12.08.2020
LT12.08.2020
SE12.08.2020
BG12.11.2020
NO12.11.2020
GR13.11.2020
Former [2021/08]FI12.08.2020
LT12.08.2020
SE12.08.2020
BG12.11.2020
NO12.11.2020
Former [2021/07]FI12.08.2020
LT12.08.2020
NO12.11.2020
Documents cited:Search[XI]WO2009006389  (SUNESIS PHARMACEUTICALS INC [US], et al) [X] 1-3,7-9,15 * abstract * * page 48, paragraph 126 - page 49, paragraph 127 * * page 168; compound 10Da * * claims 1-30 * [I] 4-6,10-14;
 [X]WO2010064722  (TAKEDA PHARMACEUTICAL [JP], et al) [X] 1-7,15 * abstract * * page 77, line 1 - page 79, line 2; example 53; claims 1,18,24-26 *;
 [XP]  - "A Phase 1B Study of MLN2480 in Combination With MLN0128 or Alisertib, or Paclitaxel, or Cetuximab, or Irinotecan in Adult Participants With Advanced Nonhematologic Malignancies", (20141230), ClinicalTrials.gov, URL: https://clinicaltrials.gov/ct2/show/NCT02327169, (20180820), XP002784013 [XP] 1-15 * the whole document *
 [XI]  - BALANI S K ET AL, "Drug drug interaction predictions for MLN2480, an investigational pan-RAF inhibitor, based on nonclinical data", EUROPEAN JOURNAL OF CANCER, & 26TH EORTC-NCI-AACR SYMPOSIUM ON MOLECULAR TARGETS AND CANCER THERAPEUTICS; BARCELONA, SPAIN; NOVEMBER 18 -21, 2014, (201411), vol. 50, no. Suppl. 6, ISSN 0959-8049, pages 54 - 55, XP002784014 [X] 1-3,7-9,15 * Abstract 162 * [I] 4-6,10-14
 [A]  - MASANORI OKANIWA ET AL, "Discovery of a Selective Kinase Inhibitor (TAK-632) Targeting Pan-RAF Inhibition: Design, Synthesis, and Biological Evaluation of C -7-Substituted 1,3-Benzothiazole Derivatives", JOURNAL OF MEDICINAL CHEMISTRY, (20130801), vol. 56, no. 16, doi:10.1021/jm400778d, ISSN 0022-2623, pages 6478 - 6494, XP055500984 [A] 1-7,15 * the whole document *

DOI:   http://dx.doi.org/10.1021/jm400778d
International search[Y]WO2009018238  (ARDEA BIOSCIENCES INC [US], et al) [Y] 14, 15 * entire document *;
 [XY]US2010183600  (LAPIERRE JEAN-MARC [US], et al) [X] 1, 2, 17 * entire document * [Y] 3, 10-15, 18;
 [Y]US2012214828  (HATZIVASSILIOU GEORGIA [US], et al) [Y] 11-13 * entire document *;
 [Y]WO2013144923  (TAKEDA PHARMACEUTICAL [JP]) [Y] 3, 10-15, 18 * entire document *;
 [PX]WO2015148828  (MILLENNIUM PHARM INC [US]) [PX] 1-3, 10-15, 17, 18* entire document *
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.